Trial results

A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus

NCT06925334 on ClinicalTrials.gov · last registry update 2025-04-13

An unusually large phase 4: 170 participants, more than double the 72 typical for the stage. Its estimated completion date, 31 December 2025, has passed with no update to the record. Primary outcome, as filed: Time to blood glucose compliance. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

ENROLLING_BY_INVITATION

Phase

P4

Drug

liraglutide

Victoza, Xultophy, Saxenda

Sponsor

Beijing Tsinghua Chang Gung Hospital

Sponsor type

Other

Enrollment

170

Started

2024-05-20

Primary completion

2025-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Time to blood glucose compliance

Conditions studied

Type 2 Diabetic Patients

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.